<DOC>
	<DOCNO>NCT02499692</DOCNO>
	<brief_summary>Prospective , multicenter , single-arm study , enroll 100 patient 10 site across China , primary endpoint Technical success .</brief_summary>
	<brief_title>SYNERGY China : Assess SYNERGY Stent China</brief_title>
	<detailed_description>The study To evaluate clinical peri-procedural angiographic outcome SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System treatment subject atherosclerotic lesion ( ) ≤34 mm length ( visual estimate ) native coronary artery ≥2.25 mm ≤4.0 mm diameter ( visual estimate ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>Key 1 . Subject must least 18 75 year age 2 . Subject eligible percutaneous coronary intervention ( PCI ) 3 . Target lesion ( ) must locate native coronary artery visually estimate reference vessel diameter ( RVD ) ≥2.25 mm ≤4.0 mm , length must ≤34* mm ( visual estimate ) , Target lesion ( ) must visually estimate stenosis ≥50 % &lt; 100 % thrombolysis Myocardial Infarction ( TIMI ) flow &gt; 1 Key 1 . Planned PCI ( include stag procedure ) CABG index procedure 2 . Subject range complete blood count ( CBC ) value determine study physician clinically significant . 3 . Subject dialysis baseline serum creatinine level &gt; 2.0 mg/dL ( 177µmol/L ) 4 . Planned treatment 3 lesion , Planned treatment lesion 2 major epicardial vessel , Planned treatment single lesion 1 stent 5 . Target lesion ( ) locate within 3 mm origin leave anterior descending ( LAD ) coronary artery leave circumflex ( LCx ) coronary artery visual estimate . 6 . Target vessel develops dissection great National Heart , Lung , Blood Institute ( NHLBI ) type C follow predilatation/pretreatment first target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>